person · Reporting owner
Salvadori Daniel Gesua Sive
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EVP AND GROUP PRESIDENT | February 27, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 146,377 |
Ending reported balance
After 2026-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-27 · Tax withholding · Disposed 6,615 · Balance 147,262 Row 2 · 2026-03-02 · Sale · Disposed 885 · Balance 146,377 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2019 Filed Jun 13, 2019 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,331 | $82.00 | $273,142.00 |
DisclosureSEC source: 0001179110-19-007613 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,148 Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,269 | $82.00 | $596,058.00 |
DisclosureSEC source: 0001179110-19-007613 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,479 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,664 | $78.00 | $129,792.00 |
DisclosureSEC source: 0001179110-19-003124 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,748 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,097 | $77.23 | $857,021.31 |
DisclosureSEC source: 0001179110-19-003124 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,412 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 162,430 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002647 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,430 Underlying: Common shares · 162,430 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 54,143 on February 22, 2020, 54,143 on February 22, 2021, and 54,144 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 30,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002647 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,509 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,800 | $73.39 | $352,276.80 |
DisclosureSEC source: 0001179110-18-011958 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,521 Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $73.40 | $14,680.20 |
DisclosureSEC source: 0001179110-18-011958 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,321 Read SEC document |
| July 21, 2018 Filed Jul 24, 2018 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,060 | $63.32 | $67,119.20 |
DisclosureSEC source: 0001179110-18-009887 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,521 Read SEC document |
| May 18, 2018 Filed May 21, 2018 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $61.50 | $61,500.00 |
DisclosureSEC source: 0001179110-18-007253 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,581 Read SEC document |
| May 17, 2018 Filed May 21, 2018 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $61.05 | $122,092.00 |
DisclosureSEC source: 0001179110-18-007253 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,581 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 905 | $58.97 | $53,368.76 |
DisclosureSEC source: 0001179110-18-003314 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,581 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,578 | $60.55 | $519,397.90 |
DisclosureSEC source: 0001179110-18-003314 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,486 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 182,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002518 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,935 Underlying: Common shares · 182,935 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,979 on 02/16/2019, 60,978 on 2/16/2020, and 60,978 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 33,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002518 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,064 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,319 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · derivative · entry 10 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,479 Underlying: Common shares · 28,319 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,700 | $54.94 | $422,999.50 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 9 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,798 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,897 | $54.93 | $378,852.21 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 8 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,498 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.92 | $5,492.14 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 7 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,395 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $54.92 | $104,348.00 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 6 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,495 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.92 | $10,983.00 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,395 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.91 | $10,982.20 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,595 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,483 | $54.91 | $81,431.53 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,795 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,839 | $54.90 | $540,170.94 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,278 Read SEC document |
| December 14, 2017 Filed Dec 14, 2017 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,319 | $47.00 | $1,330,993.00 |
DisclosureSEC source: 0001179110-17-015385 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 71,157 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-17-014210 · edgar.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,313 Underlying: Common shares · 71,157 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 71,157 | $55.00 | $3,913,635.00 |
DisclosureSEC source: 0001179110-17-014210 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,798 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 71,157 | $38.40 | $2,732,428.80 |
DisclosureSEC source: 0001179110-17-014210 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,319 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · derivative · entry 6 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,798 Underlying: Common shares · 28,319 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,142 | $0.00 Strike: $42.08 | $0.00 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · derivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 34,142 shares Expires 2024-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,142 | $0.00 Strike: $42.08 | $0.00 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · derivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,142 Underlying: Common shares · 34,142 shares Expires 2024-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 96,603 | $56.21 | $5,430,054.63 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,798 Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,319 | $47.00 | $1,330,993.00 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 68,284 | $42.08 | $2,873,390.72 |
DisclosureSEC source: 0001179110-17-013439 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,319 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · derivative · entry 6 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,117 Underlying: Common shares · 28,319 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,141 | $0.00 Strike: $42.08 | $0.00 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · derivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,284 Underlying: Common shares · 34,141 shares Expires 2024-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,487 | $52.61 | $288,671.07 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · nonDerivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,798 Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 62,460 | $52.95 | $3,307,257.00 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,285 Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,319 | $47.00 | $1,330,993.00 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 34,141 | $42.08 | $1,436,653.28 |
DisclosureSEC source: 0001179110-17-012749 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 21:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 49,611 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-17-010659 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,611 Underlying: Common shares · 49,611 shares Expires 2027-07-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,537 on 07/21/2018, 16,537 on 07/21/2019, and 16,537 on 07/21/2020. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 21:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010659 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,285 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,066 | $45.39 | $93,775.74 |
DisclosureSEC source: 0001179110-17-003680 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,112 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,759 | $45.46 | $216,344.14 |
DisclosureSEC source: 0001179110-17-003680 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,178 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 138,049 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002968 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,049 Underlying: Common shares · 138,049 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,017 on 2/17/2018, 46,016 on 2/17/2019, and 46,016 on 2/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002968 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,937 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 815 | $41.71 | $33,994.47 |
DisclosureSEC source: 0001179110-16-030075 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,976 Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,001 | $42.19 | $84,422.19 |
DisclosureSEC source: 0001179110-16-030075 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,791 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $39.27 | $3,926.50 |
DisclosureSEC source: 0001179110-16-020732 · edgar.xml · nonDerivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,792 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 81 | $39.26 | $3,180.22 |
DisclosureSEC source: 0001179110-16-020732 · edgar.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,892 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.